SCHEMBL23601577

SCHEMBL23601577

CN(c1cccc(-c2ccc(Cl)cc2)c1)c1nc2nncn2c2cc(CO)ccc12

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TP53 P04637 3/20 0.39
MAPT P10636 2/20 0.39
POLB P06746 1/20 0.39
SMN1; SMN2 Q16637 3/20 0.37
CYP2C9 P11712 1/20 0.36
NR4A2 P43354 1/20 0.36
KCNH2 Q12809 1/20 0.36
MGLL Q99685 2/20 0.36
FNTA P49354 1/20 0.35
FNTB P49356 1/20 0.35
TAAR1 Q96RJ0 1/20 0.32
MCHR1 Q99705 1/20 0.32
CHKA P35790 1/20 0.32
CHKB Q9Y259 1/20 0.32
AOC3 Q16853 2/20 0.32
FYN P06241 1/20 0.32
PRMT5 O14744 1/20 0.32
CYP1A2 P05177 1/20 0.32
MAT2A P31153 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29909291 0.92 MGLL (0.36) TP53MAPTSMN1; SMN2MGLLFYN
SCHEMBL23576658 0.92 MGLL (0.36) TP53MAPTSMN1; SMN2MGLLFYN
SCHEMBL29909768 0.89 FNTA (0.40) TP53MAPTPOLBSMN1; SMN2FNTA
SCHEMBL23601235 0.89 FNTA (0.40) TP53MAPTPOLBSMN1; SMN2FNTA
SCHEMBL29909218 0.89 MGLL (0.35) TP53SMN1; SMN2MGLLFNTAFNTB
SCHEMBL29909716 0.89 TP53 (0.41) TP53MGLL
SCHEMBL23577277 0.89 TP53 (0.41) TP53MGLL
SCHEMBL23576866 0.89 MGLL (0.35) TP53SMN1; SMN2MGLLFNTAFNTB
SCHEMBL23600461 0.86 AOC3 (0.38) TP53MAPTMGLLAOC3FYN
SCHEMBL29909017 0.86 AOC3 (0.38) TP53MAPTMGLLAOC3FYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220324866-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2022-10-13 US disclosed
WO-2021130638-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS CARNA BIOSCIENCES, INC. (JP) 2021-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220324866-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS DGKG, DGKB, DGKK TP53 647/4885MAPT 4206/4885POLB 3027/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.